Agios has FDA-approved mitapivat products, an early AQVESME thalassemia launch and more than $1.0B of cash and marketable securities. The diligence question is whether prescription growth and pipeline catalysts can outpace a quarterly expense base above $130M.
References
Sources used in this report
SEC datasetSEC company tickers exchange datasetRetrieved 2026-05-14 · Issuer identity, ticker, exchange and CIK cross-check.SEC APIAGIO submissions APIRetrieved 2026-05-14 · Filing chronology and latest company filings.Quarterly reportQ1 2026 Form 10-Q2026-04-29 · Latest financial statements, liquidity, product and pipeline disclosures.Earnings releaseQ1 2026 earnings release2026-04-29 · Q1 revenue, AQVESME prescriptions, cash, expenses and pipeline timing.Annual reportFY2025 Form 10-K2026-02-12 · FY2025 financials, product revenue history, employees, risks and business overview.Earnings releaseQ4 and FY2025 earnings release2026-02-12 · FY2025 revenue, AQVESME availability and year-end cash.Investor presentationJanuary 2026 corporate presentation2026-01-12 · Pipeline map, 2026 priorities and management estimates.Governance filing2026 proxy statement2026-04-24 · Management, board, ownership and compensation context.Regulator sourceFDA AQVESME thalassemia approval pageCurrent as of 2026-01-05 · Approval, indication, efficacy and REMS context.Regulator sourceFDA PYRUKYND PK deficiency approval pageCurrent as of 2022-02-17 · Approval, indication, disease context and trial support.